Risk Factors and Molecular Genomics of U.S. Patients With Chronic Liver Disease and Hepatocellular Cancer

Completed

Conditions studied: Carcinoma, Hepatocellular

In brief

To identify risk factors for the development and diagnosis of hepatocellular CA in patients with chronic hepatitis C and to use the data to ultimately develop an effective screening program.

Key facts

Study ID

NCT01034865

Run by

Stanford University

People needed

750

Starts

2001-05-01

Expected to finish

2009-06-01

Last updated by the study team

2017-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• For both experimental subjects and controls:
• Patients between older than 18 years of age of all ethnic backgrounds and genders.
• Patients with chronic liver disease
• For Experimental Subjects Only:
• Patients with HCC with a hepatic mass larger or equal to 5cm
• Patients with HCC with a hepatic mass lesion confirmed by fine needle aspirate (FNA) or by pathology in the cases of surgical resection
• Patients with HCC with a hepatic mass lesion with characteristic CT or MRI or angiographic appearance.
• For Controls Only:
• Patients with chronic liver disease without evidence of HCC confirmed by either :
• A normal AFP level
• a negative imaging study (ultrasound, CT, or MR imaging).
• Negative liver cancer on explants.
• Exclusion Criteria:
• Patients who declined to participate in the study
• Patients with a history of HIV infection
• Patients with concurrent advanced malignancy of non-hepatic origin.
• Patients with significant use of androgenic steroid.
• Patients with exposure to vinyl chloride.

Where it is running

• Stanford University School of Medicine — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.